These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 4613698)

  • 1. Multiple myeloma. A study of forty patients.
    Pick AI; Schonfeld J; Schreibman S; Frohlichman R; Pinkhas J
    Isr J Med Sci; 1974 Nov; 10(11):1371-8. PubMed ID: 4613698
    [No Abstract]   [Full Text] [Related]  

  • 2. [Therapeutic experiences in multiple myeloma].
    Sonntag R; Favre E; Martz G
    Schweiz Med Wochenschr; 1972 Nov; 102(44):1588-9. PubMed ID: 4566555
    [No Abstract]   [Full Text] [Related]  

  • 3. Peptichemio in multiple myeloma. (Preliminary results).
    Cavo M; Gobbi M; Tura S
    Haematologica; 1981 Apr; 66(2):208-15. PubMed ID: 6791997
    [No Abstract]   [Full Text] [Related]  

  • 4. Prognostic factors and survival in multiple myeloma. Analysis of 91 cases treated by melphalan and prednisone.
    Gobbi M; Cavo M; Savelli G; Baccarani M; Tura S
    Haematologica; 1980 Aug; 65(4):437-45. PubMed ID: 6774915
    [No Abstract]   [Full Text] [Related]  

  • 5. [Multiple myeloma (author's transl)].
    Nakatsuji T; Matsumoto N; Kaku K; Hiroshige Y; Oda S; Shinohara K; Yaga K; Fujii S; Miwa S; Kamei T; Nagasawa T; Tani S
    Rinsho Ketsueki; 1980 Mar; 21(3):347-55. PubMed ID: 7411874
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clinical aspects of multiple myeloma and its treatment based on a 10-year clinical experience].
    Bach I
    Orv Hetil; 1972 Apr; 113(17):981-5. PubMed ID: 5022591
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma.
    Abramson N; Lurie P; Mietlowski WL; Schilling A; Bennett JM; Horton J
    Cancer Treat Rep; 1982 Jun; 66(6):1273-7. PubMed ID: 7044535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Melphalan in multiple myeloma].
    Ben-Bassat Y
    Harefuah; 1971 Feb; 80(3):141-3. PubMed ID: 5099255
    [No Abstract]   [Full Text] [Related]  

  • 9. [On the nature of bone regeneration processes in patients with multiple myeloma treated with sarcolysin].
    Tager IL; Merkulova NV; Tseshkovskiĭ MS
    Vestn Rentgenol Radiol; 1965; 40(2):13-7. PubMed ID: 5853760
    [No Abstract]   [Full Text] [Related]  

  • 10. [Clinical contribution the the therapy of multiple myeloma with phenylalanine mustard (melphalan)].
    Giardin A; Del Mela P; Morandi GA
    Riv Crit Clin Med; 1966 Aug; 66(3):244-54. PubMed ID: 6002407
    [No Abstract]   [Full Text] [Related]  

  • 11. Multiple myeloma. Prolonged periods of remission can be produced in myelomatosis with alkylating agents.
    Leone LA; Albala MM
    R I Med J; 1965 Sep; 48(9):478-85. PubMed ID: 5213242
    [No Abstract]   [Full Text] [Related]  

  • 12. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
    Cavo M; Benni M; Ronconi S; Fiacchini M; Gozzetti A; Zamagni E; Cellini C; Tosi P; Baccarani M; Tura S;
    Haematologica; 2002 Sep; 87(9):934-42. PubMed ID: 12217805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The treatment of multiple myeloma with melphalan].
    de Halleux F
    Presse Med (1893); 1967 Nov; 75(46):2307-10. PubMed ID: 6054150
    [No Abstract]   [Full Text] [Related]  

  • 14. Effectiveness of two-stage treatment of multiple myeloma with melphalan and with melphalan in combination with cyclophosphamide, carmustine, vincristine and prednisone.
    Snigurowicz J; Kraj M; Rostkowska J; Maj S; Mariańska B; Mendek E; Roszkowski S; Kilian Z; Kołakowski L
    Arch Immunol Ther Exp (Warsz); 1981; 29(2):145-53. PubMed ID: 7030265
    [No Abstract]   [Full Text] [Related]  

  • 15. Chemotherapy of multiple myeloma: melphalan--40 years old and still going strong.
    Bergsagel PL
    Biol Blood Marrow Transplant; 2003 Jan; 9(1):2-3. PubMed ID: 12533738
    [No Abstract]   [Full Text] [Related]  

  • 16. [Three cases of multiple myeloma and clinical application of melphalan treatment].
    Fukuhara M; Tsujii T; Fukuda S; Matsumori T; Fukui S
    Rinsho Ketsueki; 1972 Aug; 13(4):582-8. PubMed ID: 4674852
    [No Abstract]   [Full Text] [Related]  

  • 17. [Therapy results and clinical course in 91 cases of multiple myeloma with regard to their clinical staging (author's transl)].
    Rubio Felix D; Giraldo MP; Raichs A; García Zueco JC; Mur P; Faura MV; Ruíz-Marcuello E; Piñan MA
    Sangre (Barc); 1980; 25(1):25-34. PubMed ID: 7384962
    [No Abstract]   [Full Text] [Related]  

  • 18. Normal immunoglobulins in multiple myeloma: effect of melphalan chemotherapy.
    Alexanian R; Migliore PJ
    J Lab Clin Med; 1970 Feb; 75(2):225-33. PubMed ID: 5414404
    [No Abstract]   [Full Text] [Related]  

  • 19. [Myeloma and myelomonocytic leukemia. Role of melphalan. Ultrastructural and cytoenzymologic study].
    Marsan C; Henon P; Quillard A; Grimaldi A; Cywiner-Golenzer C; Adotti F; Dryll A; Roujeau J
    Pathol Eur; 1973; 8(4):287-98. PubMed ID: 4523953
    [No Abstract]   [Full Text] [Related]  

  • 20. [Maintenance therapy with low-dose of melphalan in multiple myeloma (author's transl)].
    Hirasawa Y; Nagaoka T; Kuto F; Tokuhiro H; Kikawada R
    Rinsho Ketsueki; 1980 Nov; 21(11):1646-54. PubMed ID: 7206225
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.